A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Public ClinicalTrials.gov record NCT02814175. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in participants with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 (Day 1 up to Week 16) is designed to compare the achievement of minimal disease activity (MDA) between participants randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the highest recommended or tolerable dose; Part 2 (Week 16 through Week 32) is designed to evaluate the maintenance or achievement of MDA on 4 different treatment regimens using adalimumab and/or MTX, with participant allocation based on the initial randomized treatment and achievement of MDA in Part 1, and with rescue treatment option.
Study identification
- NCT ID
- NCT02814175
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2016 (Actual)
- Primary completion
- Sep 23, 2019 (Actual)
- Completion
- Mar 19, 2020 (Actual)
- Last update posted
- Nov 23, 2020
2016 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AZ Arthritis & Rheum Research /ID# 161796 | Sun City | Arizona | 85351 | — |
| LeJenue Research Associates /ID# 200093 | Miami | Florida | 33126 | — |
| Deerbrook Medical Associates /ID# 158655 | Vernon Hills | Illinois | 60061 | — |
| Ochsner Clinic Foundation /ID# 155178 | Baton Rouge | Louisiana | 70836-6455 | — |
| Clinical Pharmacology Study Gr /ID# 161057 | Worcester | Massachusetts | 01605 | — |
| Shores Rheumatology, PC /ID# 162697 | Saint Clair Shores | Michigan | 48081 | — |
| Coastal Carolina Health Care /ID# 152088 | New Bern | North Carolina | 28562 | — |
| PMG Research of Wilmington LLC /ID# 152089 | Wilmington | North Carolina | 28401 | — |
| Altoona Ctr Clinical Res /ID# 152087 | Duncansville | Pennsylvania | 16635 | — |
| Metroplex Clinical Research /ID# 162486 | Dallas | Texas | 75231 | — |
| Swedish Medical Center /ID# 162051 | Seattle | Washington | 98104 | — |
| West Virginia Research Inst /ID# 157815 | South Charleston | West Virginia | 25309 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02814175, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2020 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02814175 live on ClinicalTrials.gov.